12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cetilistat: Phase III data

The double-blind, Japanese Phase III CCT-002 trial in obese patients with Type II diabetes and dyslipidemia showed that thrice-daily 120 mg cetilistat met the primary endpoint of reducing average body weight from baseline to week 52 vs. placebo (2.8% vs. 1.1%). The partners also said that...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >